Starpharma Holdings Limited (SPHRF) Price & Analysis

Compare

12 Followers

SPHRF Stock Chart & Stats

$0.21

>-$0.01(-3.96%)

At close: Jan 02 4:00 PM EST

$0.21

>-$0.01(-3.96%)

Day’s Range― - ―

52-Week Range$0.06 - $0.39

Previous CloseN/A

Volume1.00K

Average Volume (3M)3.00

Market Cap

$116.69M

Enterprise Value$152.61M

Total Cash (Recent Filing)$18.25M

Total Debt (Recent Filing)$790.00K

Price to Earnings (P/E)27.6

Beta0.14

Next Earnings

Aug 26, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)<0.01

Shares Outstanding419,915,680

10 Day Avg. Volume10

30 Day Avg. Volume3

Financial Highlights & Ratios

PEG Ratio-0.19

Price to Book (P/B)1.93

Price to Sales (P/S)7.47

P/FCF Ratio-5.40

Enterprise Value/Market Cap1.31

Enterprise Value/Revenue10.71

Enterprise Value/Gross Profit17.81

Enterprise Value/Ebitda-19.07

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)>-0.01

Revenue Forecast (FY)$10.59M

Bulls Say, Bears Say

Bulls Say

Revenue Growth MomentumSustained revenue growth of ~18% demonstrates expanding commercial traction for Starpharma’s dendrimer platform and/or product sales. Over a 2–6 month horizon this provides a firmer foundation for licensing milestones, supports partner confidence, and helps finance ongoing R&D as programs mature.

Conservative Leverage / Healthy Capital StructureLow debt and a healthy equity ratio give Starpharma financial flexibility typical biotech needs: funding development timelines, absorbing setbacks, and negotiating partner deals without immediate solvency pressure. This conservatism reduces refinancing risk across the medium term.

Relatively Strong Gross Profit MarginA relatively strong gross margin indicates the underlying dendrimer materials and platform services are scalable and can generate positive gross cash on incremental sales. If fixed R&D and SG&A can be optimized, this margin profile supports durable margin expansion as licensing and product volumes grow.

Bears Say

Negative Operating And Free Cash FlowPersistent negative operating and free cash flow drains balance sheet resources and forces reliance on external funding or milestone receipts. Over months this constrains capital available for trials, manufacturing scale-up, or commercial investment and raises dilution or financing risk if milestones lag.

Negative EBIT And Net MarginsSustained negative EBIT and net margins show operations are not yet self-sustaining despite revenue gains. This structural profitability gap implies the business will remain dependent on partner funding or capital markets until higher-margin licensing or commercial sales scale materially.

Negative Return On EquityA negative ROE signals the company is not converting invested shareholder capital into profits. Over a medium-term horizon this undermines shareholder value creation and may elevate the cost or challenge of raising new equity unless commercial milestones or margin improvements restore positive returns.

Starpharma Holdings Limited News

Starpharma Ramps Up DEP® Partnerships and Radiopharma Pipeline as Viraleze™ Sales Surge

Starpharma Holdings Limited ( ($AU:SPL) ) has issued an announcement. Starpharma reported a highly active second quarter of...

1M ago

Starpharma Seeks ASX Quotation for 1.69 Million New Ordinary Shares

The latest update is out from Starpharma Holdings Limited ( ($AU:SPL) ). Starpharma Holdings Limited has applied to...

2M ago

Starpharma Announces Lapse of 381,810 Performance Rights

Starpharma Holdings Limited ( ($AU:SPL) ) just unveiled an update. Starpharma Holdings Limited has notified the market that...

2M ago

Starpharma CEO Receives New Performance Rights

Starpharma Holdings Limited ( ($AU:SPL) ) has provided an announcement. Starpharma Holdings Limited announced a change in the...

3M ago

Starpharma Issues Unquoted Securities to Boost Employee Incentives

The latest update is out from Starpharma Holdings Limited ( ($AU:SPL) ). Starpharma Holdings Limited has announced the...

3M ago

Starpharma Announces Successful 2025 AGM Results

Starpharma Holdings Limited ( ($AU:SPL) ) just unveiled an update. Starpharma Holdings Limited announced the results of its...

4M ago

Starpharma Announces Strategic Partnerships and Growth at AGM

The latest announcement is out from Starpharma Holdings Limited ( ($AU:SPL) ). Starpharma Holdings Limited announced significant progress...

4M ago

Starpharma Secures Key Partnerships and Advances Strategic Initiatives in Q1 FY26

The latest update is out from Starpharma Holdings Limited ( ($AU:SPL) ). Starpharma Holdings Limited has announced significant...

4M ago

Starpharma Receives $5.5 Million Upfront Payment from Genentech for Oncology Collaboration

Starpharma Holdings Limited ( ($AU:SPL) ) has provided an announcement. Starpharma Holdings Limited has received an upfront payment...

5M ago

Starpharma Showcases Strategic Advances in Oncology Drug Delivery

Starpharma Holdings Limited ( ($AU:SPL) ) has shared an update. Starpharma Holdings Limited, a leader in dendrimer technology,...

5M ago

SPHRF FAQ

What was Starpharma Holdings Limited’s price range in the past 12 months?

Starpharma Holdings Limited lowest stock price was $0.06 and its highest was $0.39 in the past 12 months.

What is Starpharma Holdings Limited’s market cap?

Starpharma Holdings Limited’s market cap is $116.69M.

When is Starpharma Holdings Limited’s upcoming earnings report date?

Starpharma Holdings Limited’s upcoming earnings report date is Aug 26, 2026 which is in 172 days.

How were Starpharma Holdings Limited’s earnings last quarter?

Starpharma Holdings Limited released its earnings results on Feb 17, 2026. The company reported $0.002 earnings per share for the quarter, beating the consensus estimate of N/A by $0.002.

Is Starpharma Holdings Limited overvalued?

According to Wall Street analysts Starpharma Holdings Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Starpharma Holdings Limited pay dividends?

Starpharma Holdings Limited does not currently pay dividends.

What is Starpharma Holdings Limited’s EPS estimate?

Starpharma Holdings Limited’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Starpharma Holdings Limited have?

Starpharma Holdings Limited has 419,915,680 shares outstanding.

What happened to Starpharma Holdings Limited’s price movement after its last earnings report?

Starpharma Holdings Limited reported an EPS of $0.002 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Starpharma Holdings Limited?

Currently, no hedge funds are holding shares in SPHRF

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Starpharma Holdings Limited Stock Smart Score

Outperform

Fundamentals

Return on Equity

-41.51%

Trailing 12-Months

Asset Growth

-32.24%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Starpharma Holdings Limited

Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. It offers VivaGel, a non-antibiotic therapy for the treatment and prevention of bacterial vaginosis. The company also develops VivaGel condom, an antiviral condom; and VIRALEZE, an antiviral nasal spray. In addition, it develops DEP, a dendrimer drug delivery technology, including DEP docetaxel that is in Phase 2 clinical trials, DEP cabazitaxel that is in Phase 2 clinical trial, DEP gemcitabine that is in a Phase 1/2 clinical trials, and DEP irinotecan that is in Phase 2 clinical trials for the treatment of cancer; DEP radiotheranostics for cancer treatment and diagnosis; DEP Antibody Drug Conjugates; DEP HER-2 ADC; DEP non-oncology candidates; and DEP AZD0466, which is in Phase 1/2 clinical trials to treat haematological malignancies. The company was founded in 1996 and is headquartered in Abbotsford, Australia.